Sandra Redmond has 20 years’ experience providing expert economic and modelling advice to clients. Following a degree and masters in economics from University College Dublin (UCD), she worked as a researcher in UCD, followed by 5 years as an economic consultant in Goodbody Stockbrokers in Dublin and Econtech in Australia. Upon her return to Ireland in 2005, she joined the market access team in GlaxoSmithKline (GSK) as a health economics specialist progressing to the role of Head of Market Access in 2016.
She has lots of first-hand experience in securing reimbursement for new medicines and maintaining access for existing medicines in Ireland. In relation to new medicines, she was responsible for producing market access strategies, advisory boards, stakeholder mapping, Rapid Reviews and Health Technology Assessments (HTAs) along with pricing strategies which were used in negotiations with the HSE. Some of the HTAs she produced included those for melanoma, cervical cancer, asthma, pulmonary arterial hypertension, rotavirus vaccination and breast cancer. In relation to existing medicines, she was responsible for submissions to the HPRA on interchangeability, to the HSE on reference pricing; and to the Medicines Management Programme on preferred medicines and cost and prescribing guidance.
She has published original costing and epidemiology studies in the area of restless leg syndrome, cervical cancer and diabetes. Specifically, the “Cost of Type 2 Diabetes”, published in the Irish Medical Journal in 2007 won the overall Irish Healthcare Award in 2007. Moreover, she has a huge interest in how the Irish reimbursement process works and has recently published two studies on the impact of the Rapid Review process on reimbursement in Ireland.
She joins Salutem Insights as Managing Director. Her previous experience in economic consulting and in navigating the Irish reimbursement process means that she can successfully guide companies through the Irish reimbursement process and help solve other market access issues.